Summit Corporation Plc

Summit Therapeutics Plc

Olivier De Moor

Graham Michael Wynne

Peter David Johnson

Richard Storer

Colin Richard Dorgan

Francis Xavier Wilson

Alan Geoffrey Roach

Stephen Paul Wren

Paul James Davis

Richard Vickers

Paul Damien Price

Gary Nugent

Richard Joseph Pye

Richard John Vickers

Jonathon Mark Tinsley

Alexander Charles Weymouth-Wilson

Robert Clarkson

Renate Van Well

Disclosed are compounds of formula (I): which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by,

Antibacterial compounds

Disclosed are compounds of formula (I), which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by,. 

There are disclosed compound of Formula (1): A, A, Aand Awhich may be the same or different, represent N or CR, X is a divalent group selected from O, S(O), C&#x2550;W, NR, NC(&#x2550;O)Rand CRR, W is O, S, NR, Y is N or CR, one of R, R, R, R, Rand NRrepresents -L-R, in which L is a single bond or a linker group, additionally, R, R-R, which may be the same or different, independently represent hydrogen or a substituent and Rrepresents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO, NRR, in which Rand R, which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of Rand Rmay represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A-Aeach represent CR, then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CRR, Rand R, together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia. 

Treatment of Duchenne muscular dystrophy

Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations. 

Drug combinations for the treatment of duchenne muscular dystrophy

Provided is a process for the preparation of 5-(ethylsulfonyl)-2-(naphthalen-2-yl) benzo[d] oxazole useful in the treatment of Duchenne muscular dystrophy.

Treatment of duchenne muscular dystrophy

Growing community of inventors

Abingdon, United Kingdom

Olivier De Moor